Clinical Trial Update: A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating HMPL-523 in patients with relapsed or refractory mature B-cell neoplasms has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mature B-cell Neoplasms

Drugs mentioned

• HMPL-523

Snippet

Sponsor: Hutchison Medipharma Limited | Conditions: Mature B-cell Neoplasms | Phase 1 | Status: COMPLETED